Roche gets a leg up in the an­ti-TIG­IT race with first break­through des­ig­na­tion for PhII win­ner tiragolum­ab

In the race to ush­er in a next gen­er­a­tion of im­munother­a­pies, Roche’s Genen­tech has emerged from the pack, nab­bing the first break­through des­ig­na­tion for an an­ti-TIG­IT drug.

The phar­ma gi­ant’s tiragolum­ab plus Tecen­triq land­ed a spot in the FDA’s ex­pe­dit­ed re­view pro­gram for the first-line treat­ment of metasta­t­ic non-small cell lung can­cer (NSCLC) in those with high PD-L1 ex­pres­sion and no EGFR or ALK ge­nom­ic tu­mor aber­ra­tions, Roche said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER